TWIST1 is a prognostic factor for neoadjuvant chemotherapy for patients with resectable pancreatic cancer: a preliminary study

Abstract

Recent advances in the development of chemotherapies have helped improve the prognosis of pancreatic ductal adenocarcinoma (PDAC). However, predicting factors for the outcomes of chemotherapies (either gemcitabine or S-1) have not yet been established. We analyzed the expression of 4 major epithelial-to-mesenchymal transition-inducing transcription factors in 38 PDAC patients who received adjuvant chemotherapy after radical resection to examine the association with patients’ prognoses. The TWIST1-positive group showed a significantly poorer prognosis than the TWIST1-negative group for both the relapse‐free survival (median survival time [MST] of 8.9 vs. 18.5 months, P = 0.016) and the overall survival (MST of 15.2 vs. 33.4 months, P = 0.023). A multivariate analysis revealed that TWIST1 positivity was an independent prognostic factor for a poor response to adjuvant chemotherapies (hazard ratio 2.61; 95% confidence interval 1.10–6.79; P = 0.029). These results suggest that TWIST1 can be utilized as an important poor prognostic factor for radically resected PDAC patients with adjuvant chemotherapy, potentially including neoadjuvant therapy using these agents.

Prognostic significance of tumor budding in patients with pancreatic invasive ductal carcinoma who received neoadjuvant therapy

“…Abnormal CA19-9 concentration and positive S factor are recognized as independent risk factors for early recurrence in patients with PDAC who have received neoadjuvant therapy [ 4 ]. TWIST1, a major epithelial–mesenchymal transition (EMT)-inducing transcription factor, is recognized as a prognostic factor for neoadjuvant chemotherapy in patients with resectable PDAC [ 6 ]. Histological evaluations of therapeutic efficacy are also important for predicting prognosis.…”

“…Identifying prognostic factors in patients with pancreatic carcinoma who have received neoadjuvant therapy has assumed greater importance. Several prognostic factors for patients with PDAC who have received neoadjuvant therapy have been reported [ 4 , 6 ], but analysis of histological prognostic factors is not sufficient.…”